Annual report pursuant to Section 13 and 15(d)

16. Supplemental Disclosure of Cash Flow Information (Tables)

v3.7.0.1
16. Supplemental Disclosure of Cash Flow Information (Tables)
12 Months Ended
Dec. 31, 2016
Supplemental Cash Flow Elements [Abstract]  
Cash Flow Information
Year Ended December 31,            
    2016     2015  
Cash paid for interest   $ 1,441,160     $ 624,896  
Cash paid for income taxes   $ 157,346     $ 1,386,955  
Non-cash investing and financing activities:                
Accrued liabilities settled through the issuance of common stock and warrants   $ 2,231,829     $  
Exercise of stock options as reduction of notes payable, related party   $     $ 2,500,000  
Adjustment of goodwill   $     $ 131,270  
Assets acquired through capital leases   $     $ 1,638,884  
Acquisition of noncontrolling interest in Biohealth Medical Laboratory, Inc.   $ 259,875          
Acquisition of CollabRx   $     $ 13,510,777  
Conversions of preferred stock into common stock   $ 37,823,000     $ 25